|
|
||||||||||
|
J Am Coll Cardiol, 1995; 25:1046-1055 © 1995 by the American College of Cardiology Foundation |
University of California San Diego.
OBJECTIVES. In view of the segmental occurrence of coronary atherosclerosis, we postulated that acetylcholine may cause heterogeneous vasomotion, depending on the extent of vessel analyzed, criteria for change in vessel caliber and dose of drug administered. BACKGROUND. Previous studies have reported that acetylcholine causes constriction of atherosclerotic arteries. This dysfunction of endothelium-dependent dilation may be seen without angiographically detectable disease. METHODS. We developed algorithms to quantitate the dimensions of a single coronary artery over virtually its entire length during a control state and during graded doses of intracoronary acetylcholine. On the basis of triplicate control angiograms, the limit of detection of a change from control diameter was 0.31 mm (> or = 2 SD). RESULTS. Analysis of multiple segments (each 5.6 +/- 1.1 [mean +/- SD] mm) along a single coronary artery revealed a heterogeneous response to acetylcholine in 27 of 31 patients at the 10(-4) mol/liter dose and in 29 of 31 patients when responses at 10(-6), 10(-5) and 10(-4) mol/liter doses were combined; in this latter analysis, constriction and dilation in the same vessel occurred in 45% of the patients. With acetylcholine, most of 349 segments demonstrated no change, but the greatest frequency of vasoconstriction (24.6%) and vasodilation (6.9%) was seen at the 10(-4) mol/liter dose. Inducible vasomotion was observed as far distally as 7.3 cm from the site of acetylcholine infusion. CONCLUSIONS. Response to intracoronary acetylcholine with mild coronary disease is heterogeneous; disparate dimensional responses may occur in different segments of the same vessel. Inclusion of all analyzable regions of a coronary artery and the use of a reproducibility limit for quantitative angiography are optimal for assessment of segmental coronary vasomotion.
This article has been cited by other articles:
![]() |
E. H. Yang, J. P. McConnell, R. J. Lennon, G. W. Barsness, G. Pumper, S. J. Hartman, C. S. Rihal, L. O. Lerman, and A. Lerman Lipoprotein-Associated Phospholipase A2 Is an Independent Marker for Coronary Endothelial Dysfunction in Humans Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 106 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P. Johnson and K. L. Gould Clinical Evaluation of a New Concept: Resting Myocardial Perfusion Heterogeneity Quantified by Markovian Analysis of PET Identifies Coronary Microvascular Dysfunction and Early Atherosclerosis in 1,034 Subjects J. Nucl. Med., September 1, 2005; 46(9): 1427 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
T H Schindler, E Nitzsche, N Magosaki, I Brink, M Mix, M Olschewski, U Solzbach, and H Just Regional myocardial perfusion defects during exercise, as assessed by three dimensional integration of morphology and function, in relation to abnormal endothelium dependent vasoreactivity of the coronary microcirculation Heart, May 1, 2003; 89(5): 517 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Penny and K. L. Peterson Heterogeneity of response to lipid-lowering therapy: Reply J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2137 - 2137. [Full Text] [PDF] |
||||
![]() |
W. F. Penny, O. Ben-Yehuda, K. Kuroe, J. Long, A. Bond, V. Bhargava, J. F. Peterson, M. McDaniel, J. Juliano, J. L. Witztum, et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein J. Am. Coll. Cardiol., March 1, 2001; 37(3): 766 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Husain, N. P. Andrews, D. Mulcahy, J. A. Panza, and A. A. Quyyumi Aspirin Improves Endothelial Dysfunction in Atherosclerosis Circulation, March 3, 1998; 97(8): 716 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hasdai, R. J. Gibbons, D. R. Holmes Jr, S. T. Higano, and A. Lerman Coronary Endothelial Dysfunction in Humans Is Associated With Myocardial Perfusion Defects Circulation, November 18, 1997; 96(10): 3390 - 3395. [Abstract] [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |